Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.09.19
Views: 507

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Dr Susana Banerjee comments on data, during a press conference at the 2019 ESMO congress, from the PAOLA-1/ENGOT-ov25 trial.

This was a phase III randomised trial which looked at the maintenance combined targeted therapy of PARP inhibitor olaparib added to bevacizumab, in patients with and without a BRCA mutation.

Watch the press conference here

Watch Prof Isabelle Ray Coquard's interview with ecancer here

Read more about the study here

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation